
NEWS | ALLIED INDUSTRY

Ukko secures USD 40 M from Bayer in new Series B funding

Ukko, a biotech company with the mission to eliminate food allergies and sensitivities, has recently announced USD 40 million in new Series B funding. Ukko harnesses artificial intelligence (AI) and protein engineering to develop healthier food and therap

By **Pooja Yadav** | January 29, 2021



ukko-secures-usd-40-m-from-bayer-in-new-series-b-funding

> WordPress post #11862

Ukko to eliminate the world’s most prevalent food allergies and sensitivities.

Ukko, a biotech company with the mission to eliminate food allergies and sensitivities, has recently announced USD 40 million in new Series B funding. Ukko harnesses artificial intelligence (AI) and protein engineering to develop healthier food and therapies for food allergies. The new funding will allow Ukko to enter clinical trials with its investigational therapeutic for peanut allergies.

It will also accelerate the development of Ukko’s gluten that is designed for people with celiac and other gluten sensitivities. The round was led by Leaps by Bayer – the impact investment arm of Bayer – and was joined by Continental Grain Company, Skyviews Life Science, PeakBridge Ventures, Fall Line Capital, as well as existing investors Khosla Ventures, Innovation Endeavors, and TIME Ventures, the investment fund of Marc Benioff.

Novel approach with AI-powered platform

Ukko’s novel approach uses a proprietary AI-powered platform that precisely engineers food proteins to eliminate their allergenicity, while keeping their good biochemical and nutritional characteristics. The platform uses patient samples, computational biology, immunology, and protein engineering to make proteins that do not trigger the immune system.

Improved gluten proteins and therapy for peanut allergy

Ukko has a holistic food-to-therapy approach to solving food allergies and sensitivities. On the food side, Ukko is working on improved gluten proteins that are especially designed for people with celiac and other gluten sensitivities, which allows bakers, food companies, and home cooks to make delicious bread, pizza, pasta, and baked goods that everyone can eat. On the therapeutic side, Ukko is using its protein design platform to develop a new and promising investigational therapy for peanut allergy.

Read online: https://nuffoodsspectrum.in/news/30/16988/ukko-secures-usd-40-m-from-bayer-in-new-series-b-funding.html

© 2026 NUFFOODS Spectrum. All rights reserved.